Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD), focusing on targeted therapies for RAS-addicted cancers, will participate in the Guggenheim Healthcare Talks 2022 Oncology Conference. CEO Mark A. Goldsmith will lead a fireside chat, scheduled for 12:30 p.m. Pacific on February 10, 2022, during the virtual event from February 9-11, 2022. Interested parties can access the live webcast and a subsequent replay on the company's Events & Presentations page. Revolution Medicines is advancing its R&D pipeline with various RAS(ON) inhibitors and RAS Companion Inhibitors.

REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Guggenheim Healthcare Talks 2022 Oncology Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Details of the company’s participation are as follows:

• Guggenheim Healthcare Talks 2022 Oncology Conference
  Conference Date: February 9-11, 2022
  Fireside Chat Time/Date: 12:30 p.m. Pacific on Thursday, February 10, 2022
  Format: Virtual conference; webcast available

To access the live webcast of the fireside chat, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6236 (RAS^MULTI), RMC-6291(KRAS^G12C), RMC-9805 (KRAS^G12D) and RMC-8839 (KRAS^G13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

FAQ

When is Revolution Medicines participating in the Guggenheim Healthcare Talks 2022 Oncology Conference?

Revolution Medicines will participate in the conference from February 9-11, 2022, with a fireside chat on February 10, 2022, at 12:30 p.m. Pacific.

Who is presenting for Revolution Medicines at the Guggenheim Healthcare Talks?

Mark A. Goldsmith, CEO of Revolution Medicines, will present at the conference.

How can I access the webcast of Revolution Medicines' fireside chat?

The live webcast can be accessed via the Events & Presentations page on Revolution Medicines' website.

What is the focus of Revolution Medicines' research and development pipeline?

Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers, including RAS(ON) and RAS Companion Inhibitors.

What are some products in Revolution Medicines' pipeline?

Products include RMC-6236, RMC-6291, RMC-9805, RMC-8839, RMC-4630, and RMC-5552.